A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Luo, Yunan ^a,b   Zhao, Xinbin ^a   Zhou, Jingtian ^a   Yang, Jinglin ^a   Zhang, Yanqing ^a   Kuang, Wenhua ^a   Peng, Jian ^a,b   Chen, Ligong ^a,b,c   Zeng, Jianyang ^a  

^a TSINGHUA UNIVERSITY   (China)

^b University of Illinois at Urbana Champaign ^*  (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFUZOSIN; BISOPROLOL; CARTEOLOL; CHLORPROMAZINE; CHLORPROPAMIDE; CLONIDINE; DARIFENACIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; ISOPRENALINE; LABETALOL; METOPROLOL; MIDODRINE; NICARDIPINE; PINDOLOL; PRAZOSIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RESERPINE; RISPERIDONE; TADALAFIL; TELMISARTAN; TERAZOSIN; TETRABENAZINE; THIORIDAZINE; TIMOLOL; TOLTERODINE; UNINDEXED DRUG; CELECOXIB; CYCLOOXYGENASE 2; DRUG; PROTEIN; PROTEIN BINDING; PTGS2 PROTEIN, HUMAN;

ACCURACY ASSESSMENT; COMPUTER SIMULATION; DRUG; EXPERIMENTAL STUDY; GENOMICS; HETEROGENEITY; PERFORMANCE ASSESSMENT; PREDICTION;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; DRUG INFORMATION; DRUG PROTEIN BINDING; DRUG REPOSITIONING; DRUG TARGETING; HETEROGENEOUS NETWORK; HYDROGEN BOND; IC50; INFLAMMATORY DISEASE; LEARNING ALGORITHM; MACHINE LEARNING; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MOLECULAR DOCKING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PREDICTION; PROTEIN DATA BANK; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS; ALGORITHM; ANIMAL; BIOLOGY; C57BL MOUSE; CELL CULTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MODEL; PROCEDURES; PROTEIN DOMAIN;

ALGORITHMS; ANIMALS; CELECOXIB; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; CYCLOOXYGENASE 2; DRUG REPOSITIONING; HUMANS; MICE, INBRED C57BL; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN DOMAINS; PROTEINS;

EID: 85029583555     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00680-8     Document Type: Article

References (69)

1. Whitebread, S., Hamon, J., Bojanic, D. & Urban, L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10, 1421-1433 (2005).
2. Donald, B. R. Algorithms in Structural Molecular Biology (MIT Press, 2011).
3. Morris, G. M. et al. Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009).
4. Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206 (2007).
5. Bleakley, K. & Yamanishi, Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 25, 2397-2403 (2009).
6. Mei, J.-P., Kwoh, C.-K., Yang, P., Li, X.-L. & Zheng, J. Drug-target interaction prediction by learning from local information and neighbors. Bioinformatics 29, 238-245 (2013).
7. Xia, Z., Wu, L.-Y., Zhou, X. & Wong, S. T. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst. Biol. 4, S6 (2010).
8. van Laarhoven, T., Nabuurs, S. B. & Marchiori, E. Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 27, 3036-3043 (2011).
9. van Laarhoven, T. & Marchiori, E. Predicting drug-target interactions for new drug compounds using a weighted nearest neighbor profile. PLoS ONE 8, e66952 (2013).
10. Wang, S. & Peng, J. Network-assisted target identification for haploinsufficiency and homozygous profiling screens. PLoS Comput. Biol. 13, e1005553 (2017).
11. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
12. Mizutani, S., Pauwels, E., Stoven, V., Goto, S. & Yamanishi, Y. Relating drug-protein interaction network with drug side effects. Bioinformatics 28, i522-i528 (2012).
13. Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14621-14626 (2010).
14. Wang, W., Yang, S., Zhang, X. & Li, J. Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics 30, 2923-2930 (2014).
15. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77-96ra77 (2011).
16. Yang, F., Xu, J. & Zeng, J. in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 148 (NIH Public Access, 2014).
17. Chen, X., Liu, M.-X. & Yan, G.-Y. Drug-target interaction prediction by random walk on the heterogeneous network. Mol. Biosyst. 8, 1970-1978 (2012).
18. Fu, G. et al. Predicting drug target interactions using meta-path-based semantic network analysis. BMC Bioinformatics 17, 1 (2016).
19. Zheng, X., Ding, H., Mamitsuka, H. & Zhu, S. In Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining, 1025-1033 (ACM, 2013).
20. Tong, H., Faloutsos, C. & Pan, J.-Y. In Proceedings of the Sixth International Conference on Data Mining, 613-622 (IEEE Computer Society, 2006).
21. Cho, H., Berger, B. & Peng, J. in Research in Computational Molecular Biology, Vol. 9029 of Lecture Notes in Computer Science (ed. Przytycka, T. M.) 62-64 (Springer International Publishing, 2015). URL http: //dx.doi.org/10.1007/978-3-319-16706-0-9
22. Cho, H., Berger, B. & Peng, J. Compact integration of multi-network topology for functional analysis of genes. Cell Syst. 3, 540-548 (2016).
23. Wang, S., Cho, H., Zhai, C., Berger, B. & Peng, J. Exploiting ontology graph for predicting sparsely annotated gene function. Bioinformatics 31, i357-i364 (2015).
24. Davis, J. & Goadrich, M. The relationship between precision-recall and roc curves. in Proceedings of the 23rd International Conference on Machine learning, 233-240 (ACM, 2006).
25. Natarajan, N. & Dhillon, I. S. Inductive matrix completion for predicting gene-disease associations. Bioinformatics 30, i60-i68 (2014).
26. Singh-Blom, U. M. et al. Prediction and validation of gene-disease associations using methods inspired by social network analyses. PLoS ONE 8, e58977 (2013).
27. Wu, Y. et al. Evidence that clozapine directly interacts on the gabab receptor. Neuroreport 22, 637-641 (2011).
28. Wassef, A., Baker, J. & Kochan, L. D. Gaba and schizophrenia: a review of basic science and clinical studies. J. Clin. Psychopharmacol. 23, 601-640 (2003).
29. Uefuji, K., Ichikura, T. & Mochizuki, H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 6, 135-138 (2000).
30. Rao, P. & Knaus, E. E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharmaceut. Sci. 11, 81-110s (2008).
31. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol.Exp. Neurol. 63, 901-910 (2004).
32. Kearney, P. M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. BMJ 332, 1302-1308 (2006).
33. Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
34. Gosse, P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc. Health Risk Manag. 2, 195 (2006).
35. Clarke, B. & Duncan, L. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 291, 123-126 (1968).
36. Bianchi, M. L. et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum. 43, 1960-1966 (2000).
37. DiMeglio, L. A. & Peacock, M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J. Bone Miner. Res. 21, 132-140 (2006).
38. Rimon, G. et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl Acad. Sci. 107, 28-33 (2010).
39. Vecchio, A. J. & Malkowski, M. G. The structure of NS-398 bound to cyclooxygenase-2. J. Struct. Biol. 176, 254-258 (2011).
40. Kargman, S. et al. Mechanism of selective inhibition of human prostaglandin g/h synthase-1 and-2 in intact cells. Biochem. Pharmacol. 52, 1113-1125 (1996).
41. Kato, M., Nishida, S., Kitasato, H., Sakata, N. & Kawai, S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J. Pharm. Pharmacol. 53, 1679-1685 (2001).
42. Ariasnegrete, S., Keller, K. & Chadee, K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. 208, 582-589 (1995).
43. Mehmood, S. et al. Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease zmpste24. Nat. Chem. 8, 1152 (2016).
44. Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567-1593 (2015).
45. Chernobrovkin, A., Marin-Vicente, C., Visa, N. & Zubarev, R. A. Functional identification of target by expression proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci. Rep. 5, 11176 (2015).
46. Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).
47. Guney, E., Menche, J., Vidal, M. & Barábasi, A.-L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).
48. Cheng, F., Zhao, J., Fooksa, M. & Zhao, Z. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. J. Am. Med. Inform. Assoc. 23, 681-691 (2016).
49. Benson, S. C. et al. Identification of telmisartan as a unique angiotensin ii receptor antagonist with selective ppar?-modulating activity. Hypertension 43, 993-1002 (2004).
50. Sato, K. et al. Telmisartan ameliorates inflammatory responses in SHR-SR after tMCAO. J. Stroke Cerebrovasc. Dis. 23, 2511-2519 (2014).
51. Lanz, T. V. et al. Angiotensin ii sustains brain inflammation in mice via tgf-?. J. Clin. Invest. 120, 2782-2794 (2010).
52. Giles, F. J. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Williston Park) 16, 23-29 (2002).
53. Lubran, M. M. Hematologic side effects of drugs. Ann. Clin. Lab. Sci. 19, 114-121 (1989).
54. Töyräs, A., Ollikainen, J., Taskinen, M. & Mönkkönen, J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur. J. Pharmaceut. Sci. 19, 223-230 (2003).
55. Bengio, Y., Courville, A. & Vincent, P. Representation learning: a review and new perspectives. IEEE Trans. Pattern Anal. Mach. Intell. 35, 1798-1828 (2013).
56. Knox, C. et al. Drugbank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
57. Prasad, T. S. K. et al. Human protein reference database-2009 update. Nucleic Acids Res. 37, D767-D772 (2009).
58. Davis, A. P. et al. The comparative toxicogenomics database: update 2013. Nucleic Acids Res. 41, D1104-D1114 (2013).
59. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. 6, 343 (2009).
60. Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235-242 (2000).
61. Liu, J. et al. Differential effects of angiotensin II receptor blockers on a? generation. Neurosci. Lett. 567, 51-56 (2014).
62. Tsubaki, M. et al. Bisphosphonate-and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol. Cell. Endocrinol. 361, 219-231 (2012).
63. Durr, J. A., Hensen, J., Ehnis, T. & Blankenship, M. S. Chlorpropamide upregulates antidiuretic hormone receptors and unmasks constitutive receptor signaling. Am. J. Physiol. Renal Physiol. 278, F799-F808 (2000).
64. Aeberhard, E. E. et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem. Biophys. Res. Commun. 208, 1053-1059 (1995).
65. Rosenstock, M., Danon, A. & Rimon, G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim. Biophys. Acta 1440, 127-137 (1999).
66. Stuhlmeier, K. M., Li, H. & Kao, J. J. Ibuprofen: new explanation for an old phenomenon. Biochem. Pharmacol. 57, 313-320 (1999).
67. Gierse, J. K. et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 305, 479-484 (1995).
68. Hood, W. F. et al. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol. Pharmacol. 63, 870-877 (2003)
69. Schrödinger, L. L. C. The PyMOL molecular graphics system, version 1.8 (2015).